Human Molecular Genetics Advance Access originally published online on July 6, 2005
Human Molecular Genetics 2005 14(16):2387-2398; doi:10.1093/hmg/ddi240
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity
Department of Cell Research and Immunology, Tel Aviv University, Ramat Aviv 69978, Israel
* To whom correspondence should be addressed. Tel: +972 36409285; Fax: +972 36422046; Email: horowitzm{at}post.tau.ac.il
Received April 20, 2005; Accepted June 29, 2005
Gaucher disease (GD), an autosomal recessive disease, is characterized by accumulation of glucosylceramide mainly in cells of the reticuloendothelial system, due to mutations in the acid ß-glucocerebrosidase gene. Some of the patients suffer from neurological symptoms (type 2 and type 3 patients), whereas patients with type 1 GD do not present neurological signs. The disease is heterogeneous even among patients with the same genotype, implicating that a mutation in the glucocerebrosidase gene is required to cause GD but other factors play an important role in the manifestation of the disease. Glucocerebrosidase is a lysosomal enzyme, synthesized on endoplasmic reticulum (ER)-bound polyribosomes and translocated into the ER. Following N-linked glycosylations, it is transported to the Golgi apparatus, from where it is trafficked to the lysosomes. In this study, we tested glucocerebrosidase protein levels, N-glycans processing and intracellular localization in skin fibroblasts derived from patients with GD. Our results strongly suggest that mutant glucocerebrosidase variants present variable levels of ER retention and undergo ER-associated degradation in the proteasomes. The degree of ER retention and proteasomal degradation is one of the factors that determine GD severity.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
G. H. B. Maegawa, M. B. Tropak, J. D. Buttner, B. A. Rigat, M. Fuller, D. Pandit, L. Tang, G. J. Kornhaber, Y. Hamuro, J. T. R. Clarke, et al. Identification and Characterization of Ambroxol as an Enzyme Enhancement Agent for Gaucher Disease J. Biol. Chem., August 28, 2009; 284(35): 23502 - 23516. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Balreira, P. Gaspar, D. Caiola, J. Chaves, I. Beirao, J. L. Lima, J. E. Azevedo, and M. C. S. Miranda A nonsense mutation in the LIMP-2 gene associated with progressive myoclonic epilepsy and nephrotic syndrome Hum. Mol. Genet., July 15, 2008; 17(14): 2238 - 2243. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Hebert and M. Molinari In and Out of the ER: Protein Folding, Quality Control, Degradation, and Related Human Diseases Physiol Rev, October 1, 2007; 87(4): 1377 - 1408. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Steet, S. Chung, B. Wustman, A. Powe, H. Do, and S. A. Kornfeld The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms PNAS, September 12, 2006; 103(37): 13813 - 13818. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alfalah, M. P. Krahn, G. Wetzel, S. von Horsten, C. Wolke, N. Hooper, T. Kalinski, S. Krueger, H. Y. Naim, and U. Lendeckel A Mutation in Aminopeptidase N (CD13) Isolated from a Patient Suffering from Leukemia Leads to an Arrest in the Endoplasmic Reticulum J. Biol. Chem., April 28, 2006; 281(17): 11894 - 11900. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Liou, A. Kazimierczuk, M. Zhang, C. R. Scott, R. S. Hegde, and G. A. Grabowski Analyses of Variant Acid beta-Glucosidases: EFFECTS OF GAUCHER DISEASE MUTATIONS J. Biol. Chem., February 17, 2006; 281(7): 4242 - 4253. [Abstract] [Full Text] [PDF] |
||||



